DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Bone Healing After Dental Extraction in Postmenopausal Osteoporotic Women Treated With Alendronate Per os Weekly

Information source: Assistance Publique - H˘pitaux de Paris
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Alveolar Bone Healing After Dental Extraction

Intervention: Dental extraction (Procedure)

Phase: N/A

Status: Recruiting

Sponsored by: Assistance Publique - H˘pitaux de Paris

Official(s) and/or principal investigator(s):
Christian ROUX, MD, PhD, Study Chair, Affiliation: Cochin Hospital, Paris

Overall contact:
Philippe LESCLOUS, MD, PhD, Phone: +33 2 40 41 29 40, Email: philippe.lesclous@univ-nantes.fr

Summary

The purpose of this study is to determine whether the oral alendronate treatment of post-menopausal osteoporosis could be a risk factor for jaw bone healing after dental extraction.

Clinical Details

Official title: Bone Healing After Dental Extraction in Postmenopausal Osteoporotic Women Treated With Alendronate Per os (70 mg Weekly)

Study design: Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening

Primary outcome: Alveolar socket filled by new bone

Secondary outcome: Mucosal injury

Detailed description: Alendronate is the main oral bisphosphonate used in the treatment and the prevention of the postmenopausal osteoporosis because of its high antiresorbant ability for bone tissue. Alendronate delayed bone healing after dental extraction on animals models, murine as canine. Anti-angiogenic and anti-osteoclastic characteristics are suggested to explain this phenomenon. There is no available data in human and it is now well known that bisphosphonates are involved in the occurrence of osteonecrosis of the jaws even if this major adverse effect seems to be very seldom with oral alendronate. Moreover, bisphosphonate showed toxicity for oral mucosal cells. The main aim of this study is to quantify the impact of oral alendronate weekly treatment on bone and mucosa healing after dental extraction in postmenopausal osteoporotic women. A secondary aim is to investigate a panel of 50 peptids potentially involved in bone and mucosal healing and to detect changes in their rates by salivary proteomic approach. The investigators hope so identify salivary biomarkers of bone and/or mucosa healing in these women. Our hypothesis is that after dental extraction, bone healing could be delayed in postmenopausal osteoporotic women treated with oral weekly alendronate (BP+ group) versus matched osteoporotic women untreated with bisphosphonates (BP- group). This is a prospective and multicentric (17 investigation centers dispatched in France) study including 140 osteoporotic postmenopausal women treated weekly with oral bisphosphonates (BP+ group) and 140 osteoporotic postmenopausal women untreated with bisphosphonates (BP- group). This is a clinical follow-up study (T0, T0 + 7, T0 + 30, T0 + 90 days), a radiological study (T0, T0 + 30, T0 + 90 days), and a salivary proteomic study (T0, T0 + 30, T0 + 90 days). This is a 4 years study starting in april 2012 (anticipated date). The main investigated parameters are:

- Bone healing: Bone filling rate (in %) of the post-extractional alveolar socket (BFR)

at T0, T0 + 30 and T0 + 90 days by a radiographic approach.

- Mucosa healing: mucosal injury by metric approach at T0 and T0 + 30 days.

- Salivary biomarkers: Fifty peptides by proteomic approach at T0 and T0 + 30 days;

The investigators expect that this study will allow us to build a reference scale of bone and mucosa healing in osteoporotic postmenopausal women treated weekly by oral alendronate. This scale will be a helpful tool for dental physicians. The investigators hope also to identify salivary biomarkers variations to make a diagnosis and a prognosis tool of worse bone healing in these patients. Perspectives of this study is to constitute a national network of deleterious effect on bone healing in such women patients and to up-date guidelines in this area.

Eligibility

Minimum age: 45 Years. Maximum age: 70 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Postmenopausal osteoporotic women

- Treated with alendronate per os (70 pg weekly) for BP+ experimental group and

untreated with this therapy for the BP

- Control group

- Subjected to single root tooth extraction- 45 to 70 years of age

Exclusion Criteria:

- Maxillofacial irradiations

- Dental extraction with adjunction of material interfering with bone healing

- Severe pathologies inconsistent with this study

- Bisphosphonate treatment for BP- control group

- Women treated with denosumab (prolia®)

- Women already included to an another dental extraction

Locations and Contacts

Philippe LESCLOUS, MD, PhD, Phone: +33 2 40 41 29 40, Email: philippe.lesclous@univ-nantes.fr

Hotel-Dieu Hospital, Nantes 44042, France; Recruiting
Philippe LESCLOUS, MD, PhD, Phone: +33 2 40 41 29 40, Email: philippe.lesclous@univ-nantes.fr
Philippe LESCLOUS, MD, PhD, Principal Investigator
Additional Information

Starting date: September 2012
Last updated: April 20, 2015

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017